Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 5Completed 2Terminated 1Recruiting 1Not yet recruiting 1

Sponsor Class

OTHER 6OTHER_GOV 1INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 1

Interventions

tislelizumab 12Capecitabine 8apatinib 5Surgical Procedures, Operative 5Carboplatin 5Oxaliplatin 4Drug Therapy 4Cisplatin 4Radiation 3Paclitaxel 3Immunotherapy 3Bevacizumab 3toripalimab 2anlotinib 2Standard of Care 2Radiotherapy 2Methods 2Melphalan 2Low-Level Light Therapy 2Letrozole 2Interleukin-2 2Injections 2Cryotherapy 2130-nm albumin-bound paclitaxel 2zanubrutinib 1trastuzumab deruxtecan 1sintilimab 1pyrotinib 1pertuzumab 1obinutuzumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Not yet recruiting × OTHER_GOV × Tamoxifen × Clear all
NCT07101159 2025-08-03

Dalpiciclib as Adjuvant Therapy for HR-positive/HER2-negative Early-stage Patients

Fujian Cancer Hospital

Phase 2 Not yet recruiting
200 enrolled
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡